Gastroenterology

Acute Pancreatitis

Acute pancreatitis requires rapid confirmation, severity assessment, etiologic evaluation, and targeted supportive care. The supplied search results do not include pancreatitis-specific diagnostic criteria, fluid protocols, nutrition guidance, biliary intervention recommendations, or antimicrobial indications; management details therefore require verification against current specialty guidance.

Clinical question: How should physicians confirm acute pancreatitis, stratify severity, identify cause, and prioritize early management?

Updated August 20, 20263 minute readGastroenterology

What matters in practice

The supplied evidence does not provide pancreatitis-specific criteria or treatment recommendations; avoid substituting evidence from unrelated diagnostic, cardiovascular, or pharmacologic sources.
If acute pancreatitis occurs during sitagliptin therapy, the FDA label advises prompt discontinuation when pancreatitis is suspected and initiation of appropriate management. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006
TriVerity is a host-response assay studied in emergency patients with suspected infection or sepsis; it does not establish or exclude acute pancreatitis. NatureNatureClinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis | Nature Medicine

Evidence boundary

What the supplied evidence supports

The search set is not a pancreatitis management evidence base.

No supplied result provides acute-pancreatitis-specific diagnostic thresholds, severity classification, recommended initial fluid strategy, analgesic regimen, enteral feeding timing, imaging sequence, indications for ERCP, antibiotic criteria, or criteria for drainage or necrosectomy. Accordingly, these decisions should be verified in current pancreatitis-focused U.S. professional guidance and local pathways before use at the bedside.

The only directly relevant supplied source is the sitagliptin prescribing information, which reports postmarketing acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing cases. It instructs clinicians to discontinue sitagliptin promptly if pancreatitis is suspected and initiate appropriate management. Whether a history of pancreatitis increases risk during sitagliptin therapy is unknown. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006

Do not infer acute pancreatitis diagnosis from host-response molecular testing designed for suspected infection or sepsis. NatureNatureClinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis | Nature Medicine
Do not use this source set to select intravenous fluid type, volume, rate, antibiotic therapy, nutritional route, ERCP timing, or procedural intervention.
Medication reconciliation is clinically relevant when pancreatitis is suspected, particularly for sitagliptin exposure. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006

Supplied-source applicability to acute pancreatitis decisions
Clinical decision	Evidence available in supplied results	Point-of-care implication
Confirm acute pancreatitis	No pancreatitis-specific diagnostic criteria or laboratory thresholds supplied.	Use current specialty guidance; do not derive criteria from these results.
Assess severity or predict complications	TriVerity predicted need for mechanical ventilation, vasopressors, and/or new renal replacement therapy within 7 days among ED patients with suspected infection or sepsis; it was not validated for pancreatitis-specific severity assessment. NatureNatureClinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis \| Nature Medicine	Do not substitute this assay for pancreatitis-specific risk stratification.
Review possible medication contribution	Sitagliptin labeling includes postmarketing reports of acute pancreatitis and directs prompt discontinuation if suspected. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006	Hold sitagliptin when pancreatitis is suspected; evaluate alternative causes concurrently.
Initial treatment and interventions	No directly applicable pancreatitis treatment evidence supplied.	Verify current gastroenterology, surgery, and critical care recommendations.

Medication review

Sitagliptin when pancreatitis is suspected

This is the only pancreatitis-specific action supported by the supplied literature.

Sitagliptin is a dipeptidyl peptidase-4 inhibitor indicated to improve glycemic control in adults with type 2 diabetes. Its FDA labeling describes postmarketing reports of acute pancreatitis, including hemorrhagic and necrotizing pancreatitis. If pancreatitis is suspected after initiation or during treatment, stop sitagliptin promptly and manage the patient appropriately. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006

The label states that sitagliptin has not been studied in patients with a history of pancreatitis and that it is unknown whether such patients have increased risk while receiving the drug. This is a knowledge gap rather than a quantified contraindication. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006

Document exposure timing, dose, renal function, concomitant glucose-lowering drugs, alcohol exposure, biliary history, triglyceride status, and other plausible etiologies; the supplied evidence does not permit attribution of causality to sitagliptin alone.
Reassess the antihyperglycemic regimen after sitagliptin discontinuation. The supplied label supports renal-function-based sitagliptin dose adjustment but does not provide an acute-pancreatitis-specific replacement strategy. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006
Sitagliptin monotherapy has low observed hypoglycemia incidence in pooled trials, but hypoglycemia increases when used with insulin or a sulfonylurea; if those agents are continued during acute illness, reassess dosing and glycemic monitoring. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006

Sitagliptin label information relevant to suspected acute pancreatitis dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006
Issue	Label-supported information	Action
Suspected pancreatitis	Postmarketing acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been reported. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006	Promptly discontinue sitagliptin and initiate appropriate management. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006
Prior pancreatitis	Not studied; whether prior pancreatitis increases risk is unknown. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006	Use individualized risk-benefit assessment; seek current diabetes and pancreatitis guidance.
Renal function	The label recommends assessment before starting and periodically thereafter; dose reduction is specified for moderate or severe renal impairment and ESRD. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006	Review renal function during acute illness, but do not infer pancreatitis treatment from renal dose tables.

Diagnostic stewardship

Avoid misapplying sepsis biomarkers to pancreatitis

Inflammatory presentations overlap clinically but not diagnostically.

A prospective validation study evaluated the FDA-cleared TriVerity host-response assay in adults presenting to emergency departments with suspected acute infection or sepsis. The assay generates bacterial, viral, and severity scores from expression of 29 host-response mRNAs and was evaluated against adjudicated infection status and a composite of mechanical ventilation, vasopressor use, or new renal replacement therapy within 7 days. NatureNatureClinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis | Nature Medicine

Acute pancreatitis may produce systemic inflammation and organ dysfunction, but the supplied study did not validate TriVerity for diagnosing pancreatitis, distinguishing sterile pancreatic inflammation from pancreatitis-related infection, or guiding pancreatitis-specific treatment. A high severity score should not be interpreted as proof of pancreatitis severity, and a low bacterial score should not be used to decide against evaluation for infected pancreatic necrosis or another source of infection. NatureNatureClinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis | Nature Medicine

Use host-response test results, if obtained for an independent sepsis evaluation, only within the population and intended clinical context studied. NatureNatureClinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis | Nature Medicine
A diagnostic test's accuracy depends on its intended use, target population, reference standard, and disease prevalence; extrapolation beyond the validation setting can introduce clinically important error. NatureNatureA unified framework for diagnostic test development and evaluation during outbreaks of emerging infections
When systemic inflammation accompanies abdominal pain, preserve parallel evaluation for pancreatitis, biliary disease, ischemia, perforation, cholangitis, and infection rather than allowing a single biomarker to collapse the differential diagnosis. The supplied evidence does not provide a validated pathway for this distinction.

Limits of applying supplied diagnostic evidence to acute pancreatitis
Test or framework	Studied purpose	Not established for acute pancreatitis
TriVerity NatureNatureClinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis \| Nature Medicine	Likelihood of bacterial infection, viral infection, and need for specified critical-care interventions within 7 days in adults with suspected infection or sepsis. NatureNatureClinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis \| Nature Medicine	Diagnosis of pancreatitis; pancreatitis etiology; pancreatic necrosis; infected necrosis; need for ERCP, drainage, or surgery.
Diagnostic-test evaluation framework NatureNatureA unified framework for diagnostic test development and evaluation during outbreaks of emerging infections	Methodologic principles for test development and evaluation during emerging infectious disease outbreaks. NatureNatureA unified framework for diagnostic test development and evaluation during outbreaks of emerging infections	A pancreatitis diagnostic or management algorithm.

Common questions

Should sitagliptin be continued when acute pancreatitis is suspected?

No. The sitagliptin label directs prompt discontinuation if pancreatitis is suspected and initiation of appropriate management. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006

Does a history of pancreatitis contraindicate sitagliptin?

The supplied FDA labeling states that sitagliptin has not been studied in patients with prior pancreatitis and that any increased risk in this group is unknown. dailymed nlm nihdailymed nlm nihThese highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA® (sitagliptin) TabletsInitial U.S. Approval: 2006

Can TriVerity confirm or exclude acute pancreatitis?

No. The supplied validation study concerns bacterial and viral infection likelihood and short-term critical-care needs in suspected infection or sepsis, not pancreatitis diagnosis or severity. NatureNatureClinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis | Nature Medicine

What pancreatitis-specific treatment protocol can be derived from these sources?

None. The supplied results lack direct evidence for diagnostic criteria, fluid resuscitation, analgesia, nutrition, antibiotics, ERCP, drainage, or necrosectomy in acute pancreatitis.